Exhibit 99.1

News release via Canada NewsWire, Toronto 416-863-9350

	    Attention Business Editors:
	    Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer

	    TORONTO, Jan. 22 /CNW/ - Lorus Therapeutics Inc. (TSX: LOR; AMEX: LRP), a
biopharmaceutical company dedicated in the research and development of
pharmaceutical products and technologies for the management of cancer,
announced today that it has strengthened its management team with the
appointment of Mr. Peter Korth to the post of Chief Financial Officer (CFO).
	    Mr. Korth has previously held senior financial and business development
positions including CFO in several private and public companies including
DRI Capital (formerly known as Drug Royalty Corp.), Clean Power Income Fund,
TransAlta Corporation and Indal Limited where he has been responsible for
capital and credit markets, transaction structuring, managing subsidiary
reorganizations, risk management practices as well as international business
development in Asia and Australia.
	    "Mr. Korth brings significant expertise in corporate finance, investor
relations, corporate governance and compliance to the management team at
Lorus," said Dr. Aiping Young, Lorus' President and CEO. "We believe Lorus
will benefit from Peter's track record in developing and bringing an exemplary
combination of business judgment, professional skills and integrity."

	    About Lorus

	    Lorus is a biopharmaceutical company focused on the research and
development of novel therapeutics in cancer. Lorus' goal is to capitalize on
its research, preclinical, clinical and regulatory expertise by developing new
drug candidates that can be used, either alone, or in combination with other
drugs, to successfully manage cancer. Through its own discovery efforts and an
acquisition and in-licensing program, Lorus is building a portfolio of
promising anticancer drugs. Lorus has completed one Phase II and one Phase III
clinical trial. Lorus Therapeutics Inc. is listed on the Toronto Stock
Exchange under the symbol LOR, and on the American Stock Exchange under the
symbol LRP.

	    Forward looking statements

	    This press release contains forward-looking statements within the meaning
of Canadian and U.S. securities laws. Such statements include, but are not
limited to, statements relating to: financings and corporate reorganizations,
the establishment of corporate alliances, the Company's plans, objectives,
expectations and intentions and other statements including words such as
"continue", "expect", "intend", "will", "should", "would", "may", and other
similar expressions. Such statements reflect our current views with respect to
future events and are subject to risks and uncertainties and are necessarily
based upon a number of estimates and assumptions that, while considered
reasonable by us are inherently subject to significant business, economic,
competitive, political and social uncertainties and contingencies. Many
factors could cause our actual results, performance, achievements or the
transactions described in this press release to be materially different from
any future results, performance, achievements or transactions described in
this press release, if at all, that may be expressed or implied by such
forward-looking statements, including, among others: the progress of
negotiations; our ability to obtain regulatory, security holder and other
approvals; our ability to obtain the capital required for research and
operations; the inherent risks in early stage drug development including
demonstrating efficacy; development time/cost and the regulatory approval
process; the progress of our clinical trials; our ability to find and enter
into agreements with potential partners; our ability to attract and retain key
personnel; changing market conditions; and other risks detailed from
time-to-time in our ongoing quarterly filings, annual information forms,
annual reports and annual filings with Canadian securities regulators and the
United States Securities and Exchange Commission.
	    Should one or more of these risks or uncertainties materialize, or should
the assumptions set out in the section entitled "Risk Factors" in our filings
with Canadian securities regulators and the United States Securities and
Exchange Commission underlying those forward-looking statements prove
incorrect, actual results may vary materially from those described herein.
These forward-looking statements are made as of the date of this press release
and we do not intend, and do not assume any obligation, to update these
forward-looking statements, except as required by law. We cannot assure you
that such statements will prove to be accurate as actual results and future
events could differ materially from those anticipated in such statements.
Investors are cautioned that forward-looking statements are not guarantees of
future performance and accordingly investors are cautioned not to put undue
reliance on forward-looking statements due to the inherent uncertainty
therein.

	    Lorus Therapeutics' recent press releases are available through the
Company's website at www.lorusthera.com. For Lorus' regulatory filings on
SEDAR, please go to Sedar.com. For SEDAR filings prior to July 10, 2007 you
will find these under the company profile for 4325231 Canada Inc.

	    %SEDAR: 00025614E          %CIK: 0000882361

	    /For further information: Lorus Therapeutics Inc., Dr. Saeid Babaei,
(416) 798-1200 ext. 490, ir(at)lorusthera.com/
	    (LOR. LRP)

CO:  Lorus Therapeutics Inc.

CNW 16:00e 23-JAN-08